These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26346403)

  • 1. Significance of the Signal Intensity of Gadoxetic Acid-enhanced MR Imaging for Predicting the Efficacy of Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma.
    Fujita N; Nishie A; Asayama Y; Ishigami K; Ushijima Y; Takayama Y; Okamoto D; Morita K; Shirabe K; Koto K; Kubo Y; Oda Y; Honda H
    Magn Reson Med Sci; 2016; 15(1):111-20. PubMed ID: 26346403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.
    Kitao A; Zen Y; Matsui O; Gabata T; Kobayashi S; Koda W; Kozaka K; Yoneda N; Yamashita T; Kaneko S; Nakanuma Y
    Radiology; 2010 Sep; 256(3):817-26. PubMed ID: 20663969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging.
    Kitao A; Matsui O; Yoneda N; Kozaka K; Shinmura R; Koda W; Kobayashi S; Gabata T; Zen Y; Yamashita T; Kaneko S; Nakanuma Y
    Eur Radiol; 2011 Oct; 21(10):2056-66. PubMed ID: 21626360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images.
    Kitao A; Matsui O; Yoneda N; Kozaka K; Kobayashi S; Koda W; Gabata T; Yamashita T; Kaneko S; Nakanuma Y; Kita R; Arii S
    Radiology; 2012 Dec; 265(3):780-9. PubMed ID: 23175543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
    Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
    Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
    Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
    Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging.
    Fujita N; Nishie A; Kubo Y; Asayama Y; Ushijima Y; Takayama Y; Moirta K; Shirabe K; Aishima S; Honda H
    Eur Radiol; 2015 Jan; 25(1):211-20. PubMed ID: 25063395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of small (≤3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: A STARD-compliant article.
    Shin SK; Kim YS; Choi SJ; Shim YS; Jung DH; Kwon OS; Choi DJ; Kim JH
    Medicine (Baltimore); 2017 Jul; 96(29):e7278. PubMed ID: 28723741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker.
    Choi JW; Lee JM; Kim SJ; Yoon JH; Baek JH; Han JK; Choi BI
    Radiology; 2013 Jun; 267(3):776-86. PubMed ID: 23401584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation.
    Tsuboyama T; Onishi H; Kim T; Akita H; Hori M; Tatsumi M; Nakamoto A; Nagano H; Matsuura N; Wakasa K; Tomoda K
    Radiology; 2010 Jun; 255(3):824-33. PubMed ID: 20501720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gadoxetic acid-enhanced MR imaging for hepatocellular carcinoma: molecular and genetic background.
    Kitao A; Matsui O; Yoneda N; Kozaka K; Kobayashi S; Koda W; Inoue D; Ogi T; Yoshida K; Gabata T
    Eur Radiol; 2020 Jun; 30(6):3438-3447. PubMed ID: 32064560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological grade of hepatocellular carcinoma correlates with arterial enhancement on gadoxetic acid-enhanced and diffusion-weighted MR images.
    Chang WC; Chen RC; Chou CT; Lin CY; Yu CY; Liu CH; Chou JM; Hsu HH; Huang GS
    Abdom Imaging; 2014 Dec; 39(6):1202-12. PubMed ID: 24869790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peri-tumoral hyperintensity on hepatobiliary phase of gadoxetic acid-enhanced MRI in hepatocellular carcinomas: correlation with peri-tumoral hyperplasia and its pathological features.
    Yoneda N; Matsui O; Kitao A; Komori T; Kozaka K; Ikeda H; Yoshida K; Inoue D; Minami T; Koda W; Kobayashi S; Gabata T
    Abdom Radiol (NY); 2018 Aug; 43(8):2103-2112. PubMed ID: 29260280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
    Jang KM; Kim SH; Kim YK; Choi D
    Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
    Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
    AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadoxetate Disodium-Enhanced MRI to Differentiate Dysplastic Nodules and Grade of Hepatocellular Carcinoma: Correlation With Histopathology.
    Channual S; Tan N; Siripongsakun S; Lassman C; Lu DS; Raman SS
    AJR Am J Roentgenol; 2015 Sep; 205(3):546-53. PubMed ID: 26295640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of gadoxetic acid-enhanced and diffusion-weighted MR imaging in evaluation of hepatocellular carcinomas with atypical enhancement pattern on contrast-enhanced multiphasic MDCT in patients with chronic liver disease.
    Kim HS; Kim SH; Kang TW; Song KD; Choi D; Park CK
    Eur J Radiol; 2015 Apr; 84(4):555-62. PubMed ID: 25617950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging Features of Gadoxetic Acid-enhanced and Diffusion-weighted MR Imaging for Identifying Cytokeratin 19-positive Hepatocellular Carcinoma: A Retrospective Observational Study.
    Choi SY; Kim SH; Park CK; Min JH; Lee JE; Choi YH; Lee BR
    Radiology; 2018 Mar; 286(3):897-908. PubMed ID: 29166246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.